Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Treatment Outcome
100%
Treatment Patterns
100%
Objective Response Rate
100%
Salivary Duct Carcinoma
100%
Adenocarcinoma Not Otherwise Specified
100%
Palliative Systemic Therapy
100%
Systemic Therapy
75%
Overall Survival
75%
Tumor
50%
Progression-free Survival
50%
Recurrence-free Survival
50%
Local Therapy
50%
Median Progression-free Survival
50%
University of Texas
25%
MD Anderson Cancer Center
25%
Metastasis
25%
Nodal Involvement
25%
Metastatic Disease
25%
Median Overall Survival
25%
Stage IVA
25%
Cox Regression Model
25%
Kaplan-Meier Method
25%
Recurrence Rate
25%
Therapy Regimen
25%
Drug Development
25%
Old Age
25%
Survival Prediction
25%
High Stage
25%
Patient Outcomes
25%
Postoperative Radiotherapy
25%
Therapy Response
25%
HER2-positive
25%
Second-line Therapy
25%
Improved Outcomes
25%
First-line Therapy
25%
Trastuzumab
25%
Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
25%
Locoregionally Advanced
25%
Positive Surgical Margin
25%
HER2-targeted Therapy
25%
Androgen Receptor-positive
25%
Salivary Gland Cancer
25%
Working Diagnosis
25%
Nodal Positive
25%
Platinum Doublet
25%
Age-stage
25%
HER2-targeted Agents
25%
Medicine and Dentistry
Systemic Therapy
100%
Adenocarcinoma
100%
Salivary Duct Carcinoma
100%
Overall Survival
66%
Progression Free Survival
66%
Diseases
33%
Recurrence Free Survival
33%
Local Therapy
33%
Tumor
33%
Treatment Response
16%
Malignant Neoplasm
16%
Metastatic Carcinoma
16%
Targeted Therapy
16%
Recurrent Disease
16%
Radiation Therapy
16%
Kaplan Meier Method
16%
Recurrence Risk
16%
Surgical Margin
16%
Androgen Receptor
16%
Trastuzumab
16%
Salivary Gland Cancer
16%
Cox Regression Model
16%
Platinum
16%